The drug, RHB-204, is a next-generation formulation of a separate candidate from RedHill, RHB-104, which showed positive results in a Phase III trial.

Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

Drinking two small glasses of cherry juice daily may help reduce gut inflammation and improve the quality of life for people ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It is more ...

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

RedHill Biopharma (RDHL) announced plans to advance its groundbreaking late-stage program for Crohn’s disease, or CD, with initiation of an ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

A CT scan confirmed Phoebe had suffered a stroke and she spent four days being tube-fed and bedridden. Tests later revealed ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...